Nucleome Therapeutics

Nucleome Therapeutics is an artificial intelligence company in Oxford, United Kingdom, founded in 2019. It has raised $48.2M across 1 round, most recently a $48.2M Series A in October 2022.

Tackling the root causes of disease hidden in our genome

Headquarters
Oxford
Employees
11–50
Founded
2019
Business Model
B2B
Total Funding
$48.2M
Last Round
$48.2M Series AOct 2022
Rounds
1

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 1 funding round and 5 investors for this company. The full record is or through the API.

About

Nucleome Therapeutics is an Oxford-based biotechnology company using 3D genomics and machine learning to discover precision medicines for complex diseases. Founded in 2019 by leading experts in gene regulation from the University of Oxford, the company decodes disease-linked non-coding genome variants by mapping the 3D architecture of the genome. Nucleome is backed by Oxford Sciences Innovation and operates from the Oxford BioEscalator. In February 2026 the company appointed Dr. Michelle Morrow as Chief Scientific Officer to advance its pipeline.

Summary

It lists 11–50 employees. It has raised $48.2M in total across 1 round, most recently a $48.2M Series A round in Oct 2022. Investors include M Ventures, Johnson & Johnson Innovation and Pfizer Ventures.

Tech & App Stack

1 technology or app tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Data from Indexed.vcUpdated
Series ASeries AOct 2022
$48.2M

Investors

Similar Companies

Isomorphic Labs

AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...

London, United Kingdom201–500Artificial Intelligence, Biotech
Series BTotal funding$2.6BMay 2026
OpenAI

OpenAI is an AI research and deployment company dedicated to ensuring that general-purpose artifi...

San Francisco, United States5001–10000Artificial Intelligence, Generative AI
Corporate RoundTotal funding$179.6BMar 2026
Anthropic

Anthropic develops reliable, interpretable, and steerable AI systems, translating frontier safety...

San Francisco, United States1001–5000Artificial Intelligence, Generative AI
Series G+Total funding$123.7BMay 2026
xAI

xAI builds AI systems, including Grok, with frontier reasoning, voice, and generative media capab...

San Francisco, United States201–500Artificial Intelligence, Generative AI
Series ETotal funding$47.4BJan 2026
Waymo

Waymo is an autonomous driving technology company with a mission to make it safe and easy for peo...

Mountain View, United States1001–5000Artificial Intelligence, Autonomous Vehicles
Venture RoundTotal funding$29.6BFeb 2026
Databricks

Databricks provides a unified data and AI platform that helps enterprises build and run applicati...

San Francisco, United States10001+Analytics, Artificial Intelligence
Series G+Total funding$20.0BJul 2026

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Nucleome Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/nucleome-therapeutics"><img src="https://indexed.vc/api/badge/company/nucleome-therapeutics" alt="Nucleome Therapeutics on Indexed.vc" width="260" height="76" /></a>